by the Skribe Team
We’re excited to announce the close of our pre-seed round to advance our wireless wearable patch built to detect cardiotoxicity caused by cancer therapies. We’ve found excellent partners in GoAhead Ventures, Marin Sonoma Impact Ventures, and a group of key angel investors – all who recognize the significant opportunity to preserve the heart health of 600,000 Americans each year at risk of heart damage during cancer treatment.
Potent cancer therapies are more powerful than ever – but too often the heart becomes collateral damage in the battle against cancer. With 20 million (and counting) cancer survivors in the US today, it’s more important now than ever to ensure that patients aren’t trading cancer for heart disease.
In a matter of weeks, we’ll begin our first clinical trial: Novel On-body Evaluation of Cardiovascular Health for Oncology (NOECHO). We’ll compare the performance of our wearable device against the gold standard for detection of changes in left ventricular function: cardiac ultrasound, or echocardiogram. The results of the NOECHO study will bring us closer to our vision of early detection and prevention of heart damage during treatment without the burden of frequent in-person screening appointments. Our goal is simplify care delivery for patients and oncologists while providing the highest quality measures of heart health to give patients the best chance at long, resilient survivorship.
We also want to acknowledge the contributions of our world-class clinical advisory team:
Dr. Susan Dent, President of the International Cardio-Oncology Society, Professor of Hematology/Oncology and Director of the Cardio-Oncology Clinic at U Rochester;
Dr. Javid Moslehi, the William Grossman Distinguished Professor in Cardiology and Section Chief of Cardio-Oncology & Immunology at UCSF; and
Dr. Han Zhu, Assistant Professor of Cardiovascular and Director of Translational Cardio-Oncology at Stanford.
The guidance and insights provided by our advisors have been invaluable during the early stages of development and will continue to be key to building the best possible solution for patients and providers.
We’re excited for this opportunity to accelerate our technical and clinical progress, and look forward to sharing more updates in the near future!
– The Skribe Team: Andrew, Josh, and Ryan
Leave a Reply